Patent Expiry

Patent/Exclusivity Expiry: VEMLIDY

Other upcoming events for ABUS

Patent ExpiryPatent/Exclusivity Expiry: HALAVEN
Phase 3 ReadoutPhase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: VEMLIDY — ABUS Patent Expiry | BioSniper